BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sintilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sintilimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05621499-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sintilimab: Phase na readout est. (NCT05621499)
DESCRIPTION:Sintilimab\, phase na.\nStudy: HAIC or Lenvatinib Combined With
  Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Ca
 rcinoma\nEstimated primary completion: November 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05621499
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05429463-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05429463)
DESCRIPTION:Sintilimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Sq
 uamous Cell NSCLC（neoSCORE Ⅱ）\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 29463
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06198907-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06198907)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Goli
 docitinib in Combination With Sintilimab for PD-L1 Selected Treatment Loca
 lly Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06198907
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680115-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06680115)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Neoadjuvant and Adjuvant Sintilim
 ab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage
  TanyN3M0 Nasopharyngeal Carcinoma\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0668011
 5
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156019-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07156019)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab in Combination With Su
 rufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07156019
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05918094-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05918094)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Comparing Modified XELOX Plus Sin
 tilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HE
 R2-negative Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05918094
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714708-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06714708)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low 
 Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant
  Therapy for Stage II-III NSCLC\nEstimated primary completion: 1 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06714708
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268677-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07268677)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Single-arm Clinical Study Evalu
 ating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant 
 Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.\nE
 stimated primary completion: 1 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07268677
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04512534-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sintilimab: Phase 2 readout est. (NCT04512534)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Chidamid
 e in Treating Peripheral T Cell Lymphoma\nEstimated primary completion: 1 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04512534
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747169-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06747169)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in L
 ocally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell 
 Lung Cancer: a Single-arm\, Multicenter Clinical Study\nEstimated primary 
 completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06747169
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007767-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07007767)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Exploring Sintilimab + Bevacizuma
 b + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior The
 rapies）\nEstimated primary completion: 30 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07007767
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031285-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06031285)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Perioperative Sintilimab Plus Bev
 acizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Cl
 inical Trial\nEstimated primary completion: 30 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06031285
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254858-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07254858)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Combined Chemo-immunotherapy Plus
  SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer\nEstimate
 d primary completion: 30 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07254858
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06314334-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06314334)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Screening Study of Combined Seque
 ntial Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphom
 a\nEstimated primary completion: 30 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06314334
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054906-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06054906)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Neoadjuvant of Sintilimab Combine
 d Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Ga
 stric Cancer\nEstimated primary completion: 30 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06054906
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Combination With Sintilimab and X
 ELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal C
 ancer\nEstimated primary completion: 30 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06494943-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06494943)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Induction IBI110 and Sintilimab
  with Chemotherapy in LA HNSCC\nEstimated primary completion: 31 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06494943
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742411-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06742411)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: XELOX Combined With Sintilimab 
 and HBO for Advanced or Metastatic GC/GEJC\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sin
 tilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06742411
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05998122-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT05998122)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Total Neoadjuvant Chemoradiothera
 py Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal C
 ancerPatients With Locally Advanced Rectal Cancer: A Prospective\, Single 
 Arm\, Exploratory Study\nEstimated primary completion: 31 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05998122
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555471-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06555471)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Single-arm\, Phase II Explorato
 ry Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Pa
 tients With Locally Advanced Gastric Cancer\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/si
 ntilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06555471
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812039-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06812039)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: HAIC Combined with Donafenib and 
 Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcin
 oma Patients At High Risk of Recurrence\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06812039
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06013618-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06013618)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Clinical Analysis of Naxitamab (h
 u3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neur
 oblastoma\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06013618
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468630-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07468630)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Tolecizumab Plus Chemoimmunothera
 py for pMMR/MSS Locally Advanced Colon Adenocarcinoma\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07468630
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730373-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06730373)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: First-line Treatment With RC48 Pl
 us Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06730373
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07852091-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07852091)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Novel Combination Therapeutic S
 trategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection 
 (A)\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07852091
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07077512-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07077512)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Relmacabtagene Autoleucel Combine
 d With Sintilimab for Relapsed/Refractory B-cell Lymphoma\nEstimated prima
 ry completion: 15 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07077512
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06761027-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06761027)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: mFOLFIRINOX Plus Anlotinib and 
 Sintilimab for Advanced Pancreatic Cancer\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 61027
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07411781-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sintilimab: Phase 1 readout est. (NCT07411781)
DESCRIPTION:Sintilimab\, phase 1.\nStudy: PIN in Combination With Sintilima
 b in Previously Treated pMMR/MSS CRC With Hepatic Metastases\nEstimated pr
 imary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07411781
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492342-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07492342)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Fulz
 erasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for
  Resectable KRAS G12C-Mutant NSCLC\nEstimated primary completion: 31 March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749234
 2
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560488-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07560488)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Ipilimumab N01 Combined With Sint
 ilimab\, Bevacizumab Biosimilar\, and Hepatic Arterial Infusion Chemothera
 py as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocell
 ular Carcinoma\nEstimated primary completion: April 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07560488
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457281-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Sintilimab: Phase 1 readout est. (NCT07457281)
DESCRIPTION:Sintilimab\, phase 1.\nStudy: GV20-0251 and Sintilimab for Neoa
 djuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A S
 ingle-Arm Study\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07457281
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888674-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06888674)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Personalized Tumor Neoantigen M
 RNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.\nEstim
 ated primary completion: 1 April 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06888674
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888648-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06888648)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Personalized Tumor Neoantigen M
 RNA Therapy for Advanced Pancreatic Cancer.\nEstimated primary completion:
  1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06888648
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06956716-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06956716)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Personalized Tumor Neoantigen m
 RNA Therapy for Advanced Intrahepatic Cholangiocarcinoma\nEstimated primar
 y completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06956716
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06995105-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06995105)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Personalized Tumor Neoantigen m
 RNA Therapy for Advanced Hepatocellular Carcinoma\nEstimated primary compl
 etion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06995105
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06397222-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06397222)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus Bevacizumab and S
 IRT for Intermediate-advanced HCC\nEstimated primary completion: 30 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06397222
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07022301-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07022301)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus Anlotinib as Seco
 nd or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1
 /L1 Therapy\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07022301
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014215-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07014215)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PD-1
  Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced 
 NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy\nEstimated primary 
 completion: May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07014215
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973330-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06973330)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus Apatinib and SOX 
 as First-line Treatment in Patients With AFP Gastric or Gastroesophageal J
 unction Adenocarcinoma\nEstimated primary completion: 1 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06973330
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07658872-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07658872)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Perioperative Fruquintinib Combin
 ed With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcin
 oma\nEstimated primary completion: 19 May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07658872
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06213519-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06213519)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: HIPEC Combined With SOX and Sinti
 limab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastas
 is\nEstimated primary completion: 30 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06213519
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421298-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06421298)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pr
 ospective\, Single-arm\, Phase II Clinical Trial to Evaluate the Efficacy 
 and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Pat
 ients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung
  Cancer After Failure of First-line Immunotherapy.\nEstimated primary comp
 letion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06421298
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06405113-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06405113)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: FMT+SOX+Sintilimab As First-line 
 Treatment for Advanced Gastric Cancer\nEstimated primary completion: 1 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064051
 13
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584018-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07584018)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: The DoHAICs Study Expansion Phase
 \nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07584018
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669740-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07669740)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Study on the Efficacy and Safet
 y of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment 
 of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Thera
 py\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07669740
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06426654-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT06426654)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Sintilimab Combined With LDRT f
 or Neoadjuvant Treatment of Locally Advanced dMMR/MSI-H Gastric Cancer\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06426654
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612137-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT07612137)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Study of IBI3005 Combination Th
 erapy in Participants With Unresectable\, Locally Advanced or Metastatic S
 olid Tumors\nEstimated primary completion: 30 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07612137
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904014-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06904014)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Efficacy and Safety of Sintilimab
  Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline R
 esectable HCC\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06904014
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040098-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07040098)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Optimizing Immunotherapy Combined
  With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07040098
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831993-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07831993)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus NALIRIFOX or Gemc
 itabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Can
 cer\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07831993
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848426-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sintilimab: Phase na readout est. (NCT06848426)
DESCRIPTION:Sintilimab\, phase na\, Non-Small Cell Lung Cancer.\nStudy: Xin
 gbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Mu
 lti-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial\
 nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06848426
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025889-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT07025889)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: IBI343 Combined With Sintilimab
  Plus Chemotherapy in Gastric Cancer\nEstimated primary completion: July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07025889
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079410-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07079410)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Neoadjuvant and Adjuvant Sintilim
 ab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell
  Carcinoma\nEstimated primary completion: July 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07079410
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07088731-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07088731)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Clinical Study to Evaluate the Ef
 ficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab
  in Neoadjuvant Treatment of Locally Advanced Cervical Cancer\nEstimated p
 rimary completion: July 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07088731
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186621-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07186621)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Adjuvant Radiotherapy of Sintilim
 ab Versus TACE for HCC\nEstimated primary completion: 9 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07186621
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07310771-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07310771)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab-Nimotuzumab Induction 
 Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II\nE
 stimated primary completion: 10 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07310771
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06748508-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270725
DTEND;VALUE=DATE:20270726
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06748508)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Comparing the Efficacy of Sintili
 mab Plus Nab-POF Regimen\, Sintilimab Plus XELOX Chemotherapy\, and Lenvat
 inib\, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negativ
 e\, Metastatic Gastric Cancer\nEstimated primary completion: 25 July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06748508
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714317-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT07714317)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Phase Ib/II Multicenter Randomi
 zed Control Study of Peri-operative Treatment With Combination of CTLA-4\,
  PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)\nEstimated pr
 imary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07714317
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985798-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05985798)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Sintilimab+Bevacizumab+TACE vs. L
 envatinib+TACE for Advanced HCC\nEstimated primary completion: 31 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05985798
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061535-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07061535)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Tafoleci
 mab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cel
 l Lung Cancer\nEstimated primary completion: 1 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07061535
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379424-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07379424)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Single-arm\, Phase II\, Multi-c
 enter Clinical Trial of Sintilimab During the Perioperative Period in Pati
 ents With Resectable Locally Advanced Head and Neck Squamous Cell Carcinom
 a\nEstimated primary completion: 25 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07379424
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204094-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06204094)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Node-sparing Radiotherapy Combine
 d With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Recta
 l Cancer\nEstimated primary completion: 1 September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06204094
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621562-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07621562)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Tafolecimab Combined With Sintili
 mab and SOX in the Treatment of pMMR/MSS Gastric Cancer\nEstimated primary
  completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07621562
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788171-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06788171)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: PULSAR Combined With PD-1 Ab and 
 Chemotherapy Plus Bev. for CRLM\nEstimated primary completion: 1 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0678817
 1
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016737-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07016737)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Immunochemotherapy ± Salvage Che
 moradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma Aft
 er Definitive Chemoradiotherapy\nEstimated primary completion: 1 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701673
 7
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07656766-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07656766)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus Gossypol Acetate 
 in Advanced Colorectal Cancer\nEstimated primary completion: 15 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07656766
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178340-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07178340)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Perioperative Therapy for HER2-ne
 gative Hepatoid Adenocarcinoma of Stomach\nEstimated primary completion: 2
 0 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sin
 tilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07178340
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483009-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sintilimab: Phase 4 readout est. (NCT06483009)
DESCRIPTION:Sintilimab\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With
  Cryoablation in NSCLC\nEstimated primary completion: October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06483009
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562297-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Sintilimab: Phase 2 readout est. (NCT05562297)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Neoadjuvant/Adjuvant Sintilimab\,
  Nab-paclitaxel\, and Gemcitabine for Resectable/Borderline Resectable Pan
 creatic Cancer\nEstimated primary completion: 1 October 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05562297
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740993-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07740993)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Single-Arm Study of Sintilimab 
 and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinom
 a\nEstimated primary completion: 1 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07740993
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848569-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271023
DTEND;VALUE=DATE:20271024
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06848569)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus AVD in Pediatric 
 Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study\nEstimated primary co
 mpletion: 23 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06848569
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06604351-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06604351)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Bron
 choscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Cen
 tral Airway Obstruction\nEstimated primary completion: 31 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06604351
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309952-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07309952)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCL
 C\nEstimated primary completion: 31 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07309952
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06652412-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06652412)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: CGA Guided Ultrafractionated RT a
 nd Systemic Treatment in Elderly or Frail Patients with Inoperable Localiz
 ed CRC\nEstimated primary completion: November 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06652412
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698757-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06698757)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Different Cycles of Preoperative 
 Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instabi
 lity-high\, Locally Advanced Colorectal Cancer\nEstimated primary completi
 on: 15 November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06698757
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522411-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT07522411)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Sequential FOLFOX-HAIC-TACE Plu
 s Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Re
 sectable High-Risk Recurrence Hepatocellular Carcinoma\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07522411
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038460-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07038460)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Mu
 lticenter Phase II Randomized Trial of Limertinib Followed by Sintilimab a
 nd Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as 
 Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07038460
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506109-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07506109)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Phase II Study of Sintilimab Co
 mbined With Ipilimumab N01\, Cetuximab and Dabrafenib in Patients With Mic
 rosatellite-Stable\, BRAF V600E-Mutated Metastatic Colorectal Cancer\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07506109
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179900-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07179900)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Radiotherapy Combined With QL1706
  and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma\
 nEstimated primary completion: December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07179900
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670026-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07670026)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Intensified Adjuvant Therapy for 
 High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Te
 rm Progression\nEstimated primary completion: 1 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07670026
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739161-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06739161)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab in Combination with Ch
 emotherapy ± Local Treatment for Om-G/GEJ\nEstimated primary completion: 
 2 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sint
 ilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06739161
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220552-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06220552)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: The Efficacy and Safety of Low-do
 se Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Gli
 oblastoma\nEstimated primary completion: 30 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06220552
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018063-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07018063)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Neoadjuvant Nab-Paclitaxel Plus O
 xaliplatin\, S-1\, and Sintilimab in Early-Onset Resectable Gastric Cancer
 \nEstimated primary completion: 30 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07018063
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05472948-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT05472948)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Surufatinib and Sintilimab in Com
 bination With Capecitabine for Metastatic Adenocarcinoma of Small Intestin
 e or Appendix Carcinoma\nEstimated primary completion: 30 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05472948
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748325-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07748325)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adju
 vant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immu
 nochemotherapy and Surgery in High-Risk NSCLC\nEstimated primary completio
 n: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07748325
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Study of Precision Treatment for 
 Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/si
 ntilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06692491
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709417-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06709417)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Phase II Clinical Study of Sint
 ilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy
  for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESC
 C) (NICE-CS)\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06709417
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06752382-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06752382)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Bevacizu
 mab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06752382
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962189-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06962189)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The 
 Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion
  for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective\, Sin
 gle-Arm\, Phase II Study\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06962189
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398326-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07398326)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Anlotinib Combined With Sintilima
 b as First-line Treatment for Advanced Non-liver Metastatic Colorectal Can
 cer\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07398326
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06761846-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06761846)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Chemothe
 rapy as Adjuvant Treatment for Phase III GC and GEJ\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06761846
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581821-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07581821)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Anlotini
 b and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Car
 cinoma\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07581821
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521852-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07521852)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Phase IIa\, Single-arm\, Open-l
 abel Clinical Study to Evaluate the Efficacy\, Safety and PK of CVM-1118 i
 n Combination With Sintilimab and TACE in Participants With Incurable/Non-
 metastatic HCC\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07521852
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799077-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07799077)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Paclitaxel Polymeric Micelles and
  Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally A
 dvanced Esophageal Squamous Cell Carcinoma\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sin
 tilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07799077
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: A Study to Evaluate the Efficac
 y and Safety of IBI310 and Sintilimab Combination Therapy in Patients With
  Hepatocellular Carcinoma as First-line Treatment.\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07490262
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925243-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 3 readout est. (NCT06925243)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Neoadjuvant Apatinib Combined Wit
 h Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined 
 With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gas
 troesophageal Junction Adenocarcinoma\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6925243
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933679-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07933679)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: SCRT Combined With CAPOX and PD-1
  Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cance
 r (TORCH-E3)\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07933679
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 4 readout est. (NCT07010393)
DESCRIPTION:Sintilimab\, phase 4.\nStudy: Genotype-Driven Neoadjuvant Thera
 py for Locally Advanced Thyroid Cancer: A Real-World Cohort Study\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738042-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase na readout est. (NCT07738042)
DESCRIPTION:Sintilimab\, phase na.\nStudy: To Explore a Single-arm Phase II
  Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant 
 Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Und
 er MSS/pMMR\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07738042
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774754-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07774754)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Radiotherapy Combined With Capeox
  Chemotherapy\, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal 
 Cancer:a Prospective Clinical Trial\nEstimated primary completion: 1 Janua
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07774
 754
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352007-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280120
DTEND;VALUE=DATE:20280121
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07352007)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Stereota
 ctic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellula
 r\nEstimated primary completion: 20 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07352007
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07574528-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280306
DTEND;VALUE=DATE:20280307
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07574528)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Phase II Study of Sintilimab\, 
 Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Sta
 ge I/II Extranodal NK/T-Cell Lymphoma\nEstimated primary completion: 6 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07574
 528
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487662-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280319
DTEND;VALUE=DATE:20280320
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07487662)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: TACE or Ablation Combined With Si
 ntilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatoce
 llular Carcinoma With Intermediate-High Recurrence Risk\nEstimated primary
  completion: 19 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07487662
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518602-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07518602)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Efficacy and Safety of Chidamide+
 Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendo
 crine Carcinoma\nEstimated primary completion: 27 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07518602
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474103-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sintilimab: Phase na readout est. (NCT07474103)
DESCRIPTION:Sintilimab\, phase na.\nStudy: SCRT-NALIRIXELOX+Sintilimab as T
 NT for High-Risk LARC\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07474103
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515625-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07515625)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Efficacy of Sintilimab Combined W
 ith Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastr
 ic/Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion:
  1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07515625
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06313190-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06313190)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Combination of SBRT and Immunothe
 rapy in Small Hepatocellular Carcinoma (HSBRT2402)\nEstimated primary comp
 letion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06313190
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497985-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Sintilimab: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: A Study of Tucidinostat in Combin
 ation With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patien
 ts\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490990-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07490990)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Disitamab Vedotin Combined With S
 intilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric C
 ancer After Second-Line Treatment Failure: A Prospective\, Single-Arm Phas
 e II Clinical Trial\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07490990
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07781072-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07781072)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus Hypofractionated 
 Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and N
 eck Squamous Cell Carcinoma\nEstimated primary completion: June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07781072
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535632-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07535632)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: SBRT Followed by PD-1 Inhibitor\,
  Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Co
 lorectal Cancer\nEstimated primary completion: 1 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07535632
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603661-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07603661)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sint
 ilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC 
 NSCLC\nEstimated primary completion: 1 June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07603661
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07306663-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07306663)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Sintilimab Combined With Chemothe
 rapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A 
 Randomized Controlled Phase Ⅲ Clinical Study\nEstimated primary completi
 on: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sint
 ilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07306663
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410975-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280610
DTEND;VALUE=DATE:20280611
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07410975)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as 
 Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
 \nEstimated primary completion: 10 June 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07410975
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05427487-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sintilimab: Phase 1 readout est. (NCT05427487)
DESCRIPTION:Sintilimab\, phase 1.\nStudy: Study of Intratumoral IVX037 in P
 atients With Advanced or Metastatic Solid Tumours\nEstimated primary compl
 etion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05427487
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654530-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07654530)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Ipilimum
 ab (N01) Plus AG as First-line Therapy for uBTC.\nEstimated primary comple
 tion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 intilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07654530
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07893340-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07893340)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: First-line Treatment With Dual Im
 munotherapy Combined With Anti-angiogenesis for Unresectable Advanced Mali
 gnant Peritoneal Mesothelioma\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07893340
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722754-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07722754)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Bevacizumab\, Sintilimab\, Cetuxi
 mab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cance
 r: BOND-4 Trial\nEstimated primary completion: 31 July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07722754
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05484024-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT05484024)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: Short-course Radiotherapy Follo
 wed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer\
 nEstimated primary completion: 31 July 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05484024
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416890-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280805
DTEND;VALUE=DATE:20280806
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07416890)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Thiotepa in Combination With Pirt
 obrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or
  Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma\
 nEstimated primary completion: 5 August 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07416890
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351487-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07351487)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Neoadjuvant Chemotherapy Combined
  With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)\nEstimated p
 rimary completion: 25 September 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07351487
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194005-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07194005)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Conversion Therapy With RC48\, Si
 ntilimab\, and SOX for HER2 1+/2+ Unresectable Gastric Cancer\nEstimated p
 rimary completion: 30 September 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07194005
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328802-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07328802)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Exploration of Sintilimab + Bevac
 izumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced
 /Metastatic Cholangiocarcinoma\nEstimated primary completion: 30 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0732880
 2
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263386-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07263386)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Phase II\, Multicenter\, Random
 ized\, Controlled Clinical Study Comparing the Efficacy and Safety of Sint
 ilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive\, 
 Stage pN3 Gastric Cancer\nEstimated primary completion: October 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07263386
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177105-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07177105)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Prim
 ary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC\nEs
 timated primary completion: 1 October 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07177105
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819019-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07819019)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Phase II Study of Irinotecan Li
 posome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Adva
 nced Gastric Cancer\nEstimated primary completion: 1 October 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07819019
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859410-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Sintilimab: Phase na readout est. (NCT07859410)
DESCRIPTION:Sintilimab\, phase na.\nStudy: Sintilimab Combined With Chemora
 diotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Ju
 nction Cancer\nEstimated primary completion: 1 October 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07859410
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07878221-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07878221)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Phase II Study of Ipilimumab N0
 1 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction 
 Cancer\nEstimated primary completion: 20 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07878221
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557251-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sintilimab: Phase 1 readout est. (NCT07557251)
DESCRIPTION:Sintilimab\, phase 1.\nStudy: A Study to Evaluate the Safety\, 
 Tolerability\, and Preliminary Efficacy of BRII-5395 in Combination With S
 intilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocell
 ular Carcinoma\nEstimated primary completion: December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07557251
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331883-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07331883)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Bevacizu
 mab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocel
 lular Carcinoma (CLEAR-2)\nEstimated primary completion: 1 December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07331883
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239622-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07239622)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Liposomal Irinotecan Combined Wit
 h Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ova
 rian Clear Cell Carcinoma\nEstimated primary completion: 31 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07239622
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07350850-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07350850)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Multicenter\, Prospective Clini
 cal Trial With a Concurrent Control Evaluating Methotrexate Combined With 
 Rituximab\,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard
  of Care in Treatment-Naive PCNSL\nEstimated primary completion: 31 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07350
 850
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638631-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07638631)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Ipilimumab (N01) Plus Sintilimab 
 and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced 
 Gastric Cancer\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07638631
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797816-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07797816)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Liposomal Irinotecan Plus 5-FU/LV
  and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Ca
 ncer\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07797816
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790419-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sintilimab: Phase 4 readout est. (NCT07790419)
DESCRIPTION:Sintilimab\, phase 4.\nStudy: A Prospective\, Single-Arm\, Open
 -Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infus
 ion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Pa
 tients With Postoperative Hepatocellular Carcinoma and Microvascular Invas
 ion\nEstimated primary completion: 31 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07790419
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05363722-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Sintilimab: Phase 1 readout est. (NCT05363722)
DESCRIPTION:Sintilimab\, phase 1.\nStudy: Clinical Study on Efficacy and Sa
 fety of IBI310\, Bevacizumab Combined With Sintilimab in Advanced HCC\nEst
 imated primary completion: January 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05363722
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324824-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07324824)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus Bevacizumab Biosi
 milar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma\nEsti
 mated primary completion: January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07324824
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06584032-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Sintilimab: Phase 3 readout est. (NCT06584032)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Study of Fruquintinib Plus Sintil
 imab for Treatment of Advanced Endometrial Cancer\nEstimated primary compl
 etion: 8 January 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06584032
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492615-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290220
DTEND;VALUE=DATE:20290221
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07492615)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Clinical Study of Sintilimab Co
 mbined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastri
 c/Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion: 
 20 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sin
 tilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07492615
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692152-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07692152)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Sintilimab Versus Mitomycin in Co
 mbination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell 
 Carcinoma\nEstimated primary completion: March 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07692152
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904183-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06904183)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Lenvatinib\, Sintilimab\, and DEB
 -TACE With/Without HAIC for HCC >7 cm With PVTT\nEstimated primary complet
 ion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 intilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06904183
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699757-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Sintilimab: Phase 1 readout est. (NCT07699757)
DESCRIPTION:Sintilimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: HSK4
 1959 With Standard Therapy in Solid Tumors With MTAP Deletion\nEstimated p
 rimary completion: April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07699757
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509424-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290410
DTEND;VALUE=DATE:20290411
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07509424)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Neoadjuvant Short-course Radiothe
 rapy Followed by a Combination of Disitamab Vedotin\, Sintilimab\, and Cap
 ecitabine in Locally Advanced HER2-expressing Rectal Cance\nEstimated prim
 ary completion: 10 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07509424
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537972-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07537972)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Denosumab Strategy for Liver Canc
 er With Bone Metastases\nEstimated primary completion: 30 May 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07537972
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455617-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Sintilimab: Phase 1 readout est. (NCT07455617)
DESCRIPTION:Sintilimab\, phase 1.\nStudy: Study of ABO2102 in KRAS-Mutated 
 Solid Tumors\nEstimated primary completion: June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07455617
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594925-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07594925)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Short-Course Radiotherapy Followe
 d by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Lo
 cally Advanced Rectal Cancer: A Prospective\, Randomized\, Controlled Phas
 e II Clinical Trial\nEstimated primary completion: 1 June 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07594925
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542912-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Sintilimab: Phase na readout est. (NCT07542912)
DESCRIPTION:Sintilimab\, phase na.\nStudy: Sintilimab\, Chidamide\, and Aza
 citidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma\nEstimated
  primary completion: 1 June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07542912
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120698-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290626
DTEND;VALUE=DATE:20290627
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07120698)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adap
 tive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)\nEstimated pri
 mary completion: 26 June 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07120698
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683221-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07683221)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: SBRT Followed by Ipilimumab N01\,
  Sintilimab\, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreat
 ic Cancer\nEstimated primary completion: 15 July 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07683221
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745790-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07745790)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Safety and Efficacy of Multimodal
  Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine\, S-1\, and Si
 ntilimab in Patients With Metastatic Pancreatic Cancer\nEstimated primary 
 completion: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07745790
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07809165-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sintilimab: Phase na readout est. (NCT07809165)
DESCRIPTION:Sintilimab\, phase na.\nStudy: Sequential PD-1 Antibody and Peg
 ylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic He
 patitis B\nEstimated primary completion: September 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07809165
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840677-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07840677)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Tafolecimab Combined With Chemoim
 munotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon C
 ancer\nEstimated primary completion: 20 September 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07840677
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761286-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT07761286)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Evaluate the Safety and Efficac
 y of Combination Therapy With SYS6090 Injection for Hepatocellular Carcino
 ma\nEstimated primary completion: 30 September 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07761286
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400302-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07400302)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Combined With Chemothe
 rapy for Adjuvant Treatment of Mucosal Melanoma After Surgery\nEstimated p
 rimary completion: 30 September 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07400302
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841159-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06841159)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Personalized Ultrafractionated St
 ereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemot
 herapy and Target Therapy for Metastatic Colorectal Cancer\nEstimated prim
 ary completion: 30 September 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06841159
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879586-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT07879586)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy P
 lus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal
  Cancer (pMMR/MSS): A National Multicenter\, Prospective\, Randomized Cont
 rolled Trial\nEstimated primary completion: 1 October 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07879586
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879599-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT07879599)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy P
 lus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Adv
 anced Rectal Cancer (pMMR/MSS): A National Multicenter\, Prospective\, Ran
 domized Controlled Trial\nEstimated primary completion: 1 October 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07879599
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198464-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Sintilimab: Phase na readout est. (NCT07198464)
DESCRIPTION:Sintilimab\, phase na.\nStudy: Relmacabtagene Autoleucel Combin
 ed With Autologous Hematopoietic Stem Cell Transplantation\, Orelabrutinib
 \, and Sintilimab for Primary Central Nervous System Lymphoma\nEstimated p
 rimary completion: 1 October 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07198464
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579247-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT07579247)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Efficacy and Safety of Immune C
 heckpoint Inhibitors for Refractory Opportunistic Infections in AIDS\nEsti
 mated primary completion: December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07579247
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715565-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07715565)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Ipilimumab N01 Plus Sintilimab an
 d Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3
 -Rearranged Renal Cell Carcinoma: A Prospective\, Multicenter\, Single-Arm
 \, Phase II Clinical Trial\nEstimated primary completion: December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07715565
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756190-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07756190)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Radscopal Radiotherapy Plus Immun
 otherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metasta
 tic Nasopharyngeal Cancer: A Single-Center\, Open-Label\, Phase II Study\n
 Estimated primary completion: 30 December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07756190
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03872661-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT03872661)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant IBI308\, Bevacizumab\, Plus Pemetrexed and Carboplatin Followed by
  Surgery in Unresectable Stage III NSCLC\nEstimated primary completion: 31
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sinti
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03872661
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686796-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07686796)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Anti-PCSK9 Antibody Tafolecimab a
 nd Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiothera
 py for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective\, Multicen
 ter\, Randomized\, Open-Label\, Parallel-Controlled Trial\nEstimated prima
 ry completion: 1 January 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07686796
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917468-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300325
DTEND;VALUE=DATE:20300326
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07917468)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Sintilimab Combined With LCCRT Fo
 llowed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Ca
 ncer\nEstimated primary completion: 25 March 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07917468
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459296-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07459296)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Becotatug Vedotin Plus Sintilimab
  in Locoregionally Advanced NPC\nEstimated primary completion: 1 April 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07459296
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594340-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07594340)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: HAIC vs. TACE Combined With Sinti
 limab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)\nEstimated
  primary completion: 30 May 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07594340
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483567-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07483567)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: IBI343 in Combination With Sintil
 imab and SOX Regimen for Perioperative Treatment of Resectable\, Locally A
 dvanced Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated pri
 mary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07483567
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731607-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300720
DTEND;VALUE=DATE:20300721
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07731607)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Monotherapy in Patient
 s With Stage I-II MSI-H/dMMR Endometrial Cancer\nEstimated primary complet
 ion: 20 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/si
 ntilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07731607
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053150-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07053150)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: A Prospective\, Open-label\, Expl
 oratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Com
 bined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive S
 ystem Tumors\nEstimated primary completion: 31 December 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07053150
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371611-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07371611)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Sintilimab Plus Chemotherapy as N
 eoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell 
 Carcinoma\nEstimated primary completion: 31 December 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07371611
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05357846-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05357846)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: PD-1 Inhibitor Combined With Neoa
 djuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC
 2101)\nEstimated primary completion: 1 January 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05357846
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643623-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT07643623)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: Neoadjuvant and Adjuvant Therap
 y Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimu
 mab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma\nEs
 timated primary completion: 31 December 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07643623
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827872-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20321001
DTEND;VALUE=DATE:20321002
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07827872)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Neoadjuvant Sintilimab Plus Chemo
 therapy for cT2N0M0 Oral Squamous Cell Carcinoma\nEstimated primary comple
 tion: 1 October 2032. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07827872
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768943-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07768943)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: GELAD-Based Response-Adapted Trea
 tment for Early-Stage Extranodal NK/T-Cell Lymphoma\nEstimated primary com
 pletion: 30 June 2033. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07768943
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365008-1995@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20360630
DTEND;VALUE=DATE:20360701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06365008)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: Sintilimab Plus FOLFIRI as Second
 -line Therapy for Patients With HER2-negative Advanced Gastric Cancer\nEst
 imated primary completion: June 2036. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06365008
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
